• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome.

作者信息

Bouwmeester Romy N, van de Kar Nicole C A J, Wetzels Jack F M

机构信息

Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.

Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.

出版信息

Kidney Int. 2021 Aug;100(2):265-268. doi: 10.1016/j.kint.2021.02.033. Epub 2021 Mar 3.

DOI:10.1016/j.kint.2021.02.033
PMID:33675845
Abstract
摘要

相似文献

1
Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome.适可而止：非典型溶血性尿毒症综合征中依库珠单抗的靶向撤药
Kidney Int. 2021 Aug;100(2):265-268. doi: 10.1016/j.kint.2021.02.033. Epub 2021 Mar 3.
2
Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.依库珠单抗在日本儿童非典型溶血性尿毒症综合征患者中的安全性和有效性：上市后监测的中期分析
Clin Exp Nephrol. 2019 Jan;23(1):112-121. doi: 10.1007/s10157-018-1610-2. Epub 2018 Jul 23.
3
Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.依库珠单抗在日本成人非典型溶血性尿毒症综合征患者中的安全性和有效性：上市后监测的中期分析
Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29.
4
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.在一项长期观察性研究中，用依库珠单抗治疗非典型溶血尿毒综合征患者的结果。
BMC Nephrol. 2019 Apr 10;20(1):125. doi: 10.1186/s12882-019-1314-1.
5
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.依库珠单抗对非典型溶血性尿毒症综合征患儿是一种安全有效的治疗方法。
Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.
6
[Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report].[非典型溶血尿毒综合征的诊断与治疗挑战：一例报告]
Acta Med Port. 2019 Oct 1;32(10):673-675. doi: 10.20344/amp.10021.
7
Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.已有长期透析的非典型溶血尿毒综合征患者是否适用依库珠单抗？病例报告及文献复习。
Pediatr Nephrol. 2019 Dec;34(12):2601-2604. doi: 10.1007/s00467-019-04341-4. Epub 2019 Sep 13.
8
Eculizumab in pregnancy: a narrative overview.妊娠期间使用依库珠单抗：叙事性综述。
J Nephrol. 2019 Feb;32(1):17-25. doi: 10.1007/s40620-018-0517-z. Epub 2018 Aug 29.
9
Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.依库珠单抗治疗非典型溶血性尿毒症综合征（aHUS）的最佳疗程——一个有待以科学方式解决的问题。
Pediatr Nephrol. 2019 May;34(5):943-949. doi: 10.1007/s00467-019-4192-7. Epub 2019 Jan 28.
10
Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature.以非典型溶血尿毒综合征为表现的系统性红斑狼疮：病例报告及文献复习。
Rheumatol Int. 2024 Oct;44(10):2213-2225. doi: 10.1007/s00296-024-05558-9. Epub 2024 Mar 19.

引用本文的文献

1
Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?aHUS 的潜在遗传学：与结局和治疗停药的关联是什么？
Int J Mol Sci. 2023 Sep 24;24(19):14496. doi: 10.3390/ijms241914496.
2
Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study.原发性肾脏非典型溶血尿毒综合征患者早期停用依库珠单抗是安全且具有成本效益的：CUREiHUS研究结果
Kidney Int Rep. 2022 Oct 18;8(1):91-102. doi: 10.1016/j.ekir.2022.10.013. eCollection 2023 Jan.
3
HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.
一名 4 岁女孩因 CFH 和产志贺毒素大肠杆菌感染的 HUS 接受依库珠单抗治疗。
Pediatr Nephrol. 2023 Apr;38(4):1195-1203. doi: 10.1007/s00467-022-05694-z. Epub 2022 Aug 15.